|
|
|
| home > white papers > Contemporary Issues in Comparator Trial Supply - Clinigen CTS |
|
|
 WHITE PAPERS |
|
Clinigen CTS
|
|
Contemporary Issues in Comparator Trial Supply
|
|
The past five years has seen a great deal of change in clinical trial management. As the bio-pharma industry looks to speed development times and consolidate new product pipelines, in a quest for improved R&D efficiency, it is no surprise that phase III trial design, planning and execution in particular has been under great scrutiny. Cost of comparator agents alone has escalated to up to $100m per year for top companies (and is predicted to grow further). Consequently innovative approaches, novel project planning and increasingly close partnerships with specialist outsourcing service providers have come to the fore.
|
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
Global pharma industry gathers at CPhI Worldwide 2021 as surge in partnering expected in 2022
Over 25,000 online and 23,000 in person attendees at the world’s largest pharma trade exhibition.
CPhI
Worldwide (9-11 November, 2021), which held its first in-person event
since 2019, hosted the global pharma community at the Fiera Milano,
Milan, welcoming exhibitors and attendees from 146 countries.
More info >> |
|
 |
White Papers |
 |
|
Clinical Trials in Emerging Markets: Goldmines or Landmines?
Pharm-Olam, LLC
Over the past decade, biopharmaceutical companies
have increasingly turned to emerging markets as a way
to reduce clinical trial costs and timelines. Areas such
as Eastern Europe, India, and Latin America—with their
ready population of treatment naïve patients—can be an
answer to the intense competition for patients seen in
developed markets. Many of the countries within these
regions may now be considered as “emerged” countries
but yet, conducting trials in these regions does require
some special attention and expertise. Before deciding to
conduct studies in these areas, companies should have a
full appreciation for the ethical, medical, regulatory, legal,
and operational hurdles that must be surmounted for
success. Here we highlight a number of those issues and
offer our recommendations for how sponsor companies
can deal with them effectively.
More info >> |
|
|
|
